argenx SE
XBRU:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
XBRU:ARGX
Watchlist
Price: 577.6 EUR 2.27% Market Closed
Market Cap: 34.5B EUR
Have any thoughts about
argenx SE?
Write Note

P/FCFE
Price to FCFE

-109.4
Current
-25.9
Median
25.2
Industry
Lower than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-109.4
=
Market Cap
34.5B EUR
/
FCFE
-330.7m USD
All Countries
Close
Market Cap P/FCFE
NL
argenx SE
XBRU:ARGX
34.5B EUR -109.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 210 918.7
US
Abbvie Inc
NYSE:ABBV
314.7B USD 12.6
US
Amgen Inc
NASDAQ:AMGN
157B USD 26.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD -87.6
US
Gilead Sciences Inc
NASDAQ:GILD
112.2B USD 11.2
US
Epizyme Inc
F:EPE
94.1B EUR -427.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 79.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 24.9
US
Seagen Inc
F:SGT
39.3B EUR -58.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.5B USD -674.7
 
NL
argenx SE
XBRU:ARGX
Average P/FCFE: 30.9
Negative Multiple: -109.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 210 918.7
US
Abbvie Inc
NYSE:ABBV
12.6
US
Amgen Inc
NASDAQ:AMGN
26.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -87.6
US
Gilead Sciences Inc
NASDAQ:GILD
11.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -427.3
AU
CSL Ltd
ASX:CSL
79.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
24.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -674.7

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More